Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Endocrinology

• Publication date

  1993-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/ENDO.132.5.7682937PMID 7682937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

  2005cited by this paper
• Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells.

  1993cited by this paper
• The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.

  1992cited by this paper
• Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

  1992cited by this paper
• Carcinoma of the prostate.

  1991cited by this paper
• Activation of protein kinase-C inhibits vitamin D receptor gene expression.

  1991cited by this paper
• Stimulation of 1,25‐dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors

  1991cited by this paper
• Cloning and expression of cDNA encoding 25‐hydroxyvitamin D3 24‐hydroxylase

  1991cited by this paper
• Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

  1990cited by this paper
• Vitamin D: a modulator of cell proliferation and differentiation.

  1990cited by this paper
• Repression of c-fos transcription and an altered genetic program in senescent human fibroblasts.

  1990cited by this paper
• Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study.

  1990cited by this paper
• The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families.

  1990cited by this paper
• The Ciba Corning ACS:180 benchtop immunoassay analyzer.

  1990cited by this paper
• Hereditary 1,25-dihydroxyvitamin D resistant rickets: molecular basis and implications for the role of 1,25(OH) 2D3 in normal physiology.

  1990cited by this paper
• Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

  1990cited by this paper
• Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II.

  1989cited by this paper
• Beta‐carotene and animal fats and their relationship to prostate cancer risk. A case—control study

  1989cited by this paper
• Distribution of soltriol [1,25(OH)2-vitamin D3] binding sites in male sex organs of the mouse: an autoradiographic study.

  1989cited by this paper
• Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3.

  1989cited by this paper
• Systemic effects of vitamin D.

  1989cited by this paper
• Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.

  1989cited by this paper
• Receptors for and bioresponses to 1,25-dihydroxyvitamin D in a human colon carcinoma cell line (HT-29).

  1989cited by this paper
• Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues

  1988cited by this paper
• Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells.

  1988cited by this paper
• Diet and prostatic cancer: a case-control study in Hawaii.

  1988cited by this paper
• Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan.

  1988cited by this paper
• The steroid and thyroid hormone receptor superfamily.

  1988cited by this paper
• Cloning and expression of full-length cDNA encoding human vitamin D receptor.

  1988cited by this paper
• Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues.

  1987cited by this paper
• Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.

  1987cited by this paper
• The role of diet in prostate cancer.

  1987cited by this paper
• The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses.

  1986cited by this paper
• 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells.

  1986cited by this paper
• Retinoic acid modulation of 1,25(OH)2 vitamin D3 receptors and bioresponse in bone cells: species differences between rat and mouse.

  1985cited by this paper
• Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3. Interaction and effects of binding on receptor function.

  1984cited by this paper
• Possible significance of new target tissues for 1,25-dihydroxyvitamin D3.

  1983cited by this paper
• The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins).

  1982cited by this paper
• Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3.

  1982cited by this paper
• Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.

  1981cited by this paper
• 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture.

  1981cited by this paper
• Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

  1956cited by this paper

• Vitamin D modulates the basal secretion of inflammatory cytokines in breast cancer cells: An in-vitro study.

  2026cites this paper
• Vitamin D deficiency alters prostate epithelial differentiation and increases prostate cancer aggressiveness in ex vivo and in vivo models

  2026cites this paper
• Vitamins in the Pathogenesis of Prostate Cancer: Implications for Prevention and Therapeutic Support

  2025cites this paper
• Genistein as a Chemo-modulatory Agent: Exploring its Potential in Chemosensitization and Combinatorial Therapeutic Strategies for Cancer Treatment.

  2025cites this paper
• Methyltransferase gene-mediated antiproliferative effect of 1,25(OH)2D3 on neuroblastoma cells

  2025cites this paper
• Vitamin D3 (Calcitriol) Monotherapy Decreases Tumor Growth, Increases Survival, and Correlates with Low Neutrophil-to-Lymphocyte Ratio in a Murine HPV-16-Related Cancer Model

  2024cites this paper
• Role of Vitamins in Therapeutic and Targeting Approaches for Prostate Cancer: An Overview.

  2024cites this paper
• Genomically anchored vitamin D receptor mediates an abundance of bioprotective actions elicited by its 1,25-dihydroxyvitamin D hormonal ligand.

  2023cites this paper
• The relationship of pre-operative vitamin D and TSH levels with papillary thyroid cancer

  2023cites this paper
• Emerging perspectives: unraveling the anticancer potential of vitamin D3

  2023cites this paper
• Bone Metastases of Diverse Primary Origin Frequently Express the VDR (Vitamin D Receptor) and CYP24A1

  2022cites this paper
• Altered expression of the vitamin D metabolizing enzymes CYP27B1 and CYP24A1 under the context of prostate aging and pathologies.

  2021cites this paper
• Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton.

  2021cites this paper
• Vitamin D as therapeutic agent acting against cancers caused by proteases

  2020cites this paper
• Can we link Vitamin D deficiency to benign prostatic enlargement? An observational case control study

  2020cites this paper
• DNA damage in paediatric obesity: a promoter and predictor of cancer in adulthood

  2020cites this paper
• Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells

  2020cites this paper
• Structure-Activity Relationship Study of an Alkynylphosphonate and a Vynilphosphonate Analogues of Calcitriol.

  2020cites this paper
• S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol

  2020cites this paper
• Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.

  2020cites this paper
• The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial.

  2020cites this paper
• The role of vitamin D3 in signaling pathways – potential anticancer properties of calcitriol and its analogues

  2019cites this paper
• Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand‐independent functions

  2019cites this paper
• A Narrative Role of Vitamin D and Its Receptor: With Current Evidence on the Gastric Tissues

  2019cites this paper
• Dietary Carcinogens and DNA Adducts in Prostate Cancer.

  2019cites this paper
• Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk

  2019cites this paper
• Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells.

  2019cites this paper
• Long term deficiency of vitamin D in germ cell testicular cancer survivors

  2018cites this paper
• Metal- and redox homeostasis in prostate cancer with vitamin D3 supplementation.

  2018cites this paper
• Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging‐related prostate lesions

  2018cites this paper
• Expression of TXNIP in Cancer Cells and Regulation by 1,25(OH)2D3: Is It Really the Vitamin D3 Upregulated Protein?

  2018cites this paper
• The Role of Vitamin D Receptors in Gastric epithelial Homeostasis

  2018cites this paper
• Prostatic compensation of the vitamin D axis in African American men.

  2017cites this paper
• Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG

  2017cites this paper
• Chemoprevention and Angiogenesis

  2017cites this paper
• Association of VDR polymorphisms (Taq I and Bsm I) with prostate cancer: a new meta-analysis

  2017cites this paper
• 25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma

  2016cites this paper
• Nucleotide Excision Repair and Vitamin D—Relevance for Skin Cancer Therapy

  2016cites this paper
• Vitamin D regulates the production of vascular endothelial growth factor: A triggering cause in the pathogenesis of rheumatic heart disease?

  2016cites this paper
• Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions

  2016cites this paper
• MDM2 (Murine Double Minute 2 homolog) bindet und inhibiert den Vitamin D Rezeptor

  2016cites this paper
• 1,25-Dihydroxyvitamin D regulation of triacylglycerol accumulation in differentiated adipocytes

  2016cites this paper
• Vitamin D Signaling Modulators in Cancer Therapy.

  2016cites this paper
• Regulation of the CCN genes by vitamin D: A possible adjuvant therapy in the treatment of cancer and fibrosis.

  2016cites this paper
• The PI3K/AKT pathway in the pathogenesis of prostate cancer.

  2016cites this paper
• LEIOMYOMAS PREVALENCE IN AFRICAN AMERICANS

  2015cites this paper
• Role of vitamin D in uterine fibroid biology.

  2015cites this paper
• Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.

  2015cites this paper
• MDM2 binds and inhibits vitamin D receptor

  2015cites this paper
• Prostate Diseases and the Metabolic Syndrome

  2015cites this paper
• Connexins and Cadherin Crosstalk in the Pathogenesis of Prostate Cancer

  2015cites this paper
• Hormonal and genetic regulation of prostate cancer in Caucasian and Malaysian Chinese ethnic groups

  2015cites this paper
• Factors Affecting 25-Hydroxyvitamin D Concentration in Response to Vitamin D Supplementation

  2015cites this paper
• Plejotropowe działanie witamin D i K

  2015cites this paper
• Disparate Vitamin D Activity in the Prostate of Men with African Ancestry

  2015cites this paper
• Adaptation to Lactose in Lactase Non Persistent People: Effects on Intolerance and the Relationship between Dairy Food Consumption and Evalution of Diseases

  2015cites this paper
• TITLE: Connexins and Cadherin Cross-talk in the Pathogenesis of Prostate Cancer

  2014cites this paper
• Vitamin D and Cancer

  2014cites this paper
• A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer

  2014cites this paper
• The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

  2014cites this paper
• Phosphonate analogues of 1α, 25 dihydroxyvitamin D3 are promising candidates for antitumoural therapies.

  2014cites this paper
• Vitamin D receptor agonist EB1089 is a potent regulator of prostatic “intracrine” metabolism

  2014cites this paper
• Potent Antiproliferative Effects of 25‐Hydroxy‐16‐ene‐23‐yne‐vitamin D3 That Resists the Catalytic Activity of Both CYP27B1 and CYP24A1

  2014cites this paper
• Vitamin D3 Regulates the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells

  2014cites this paper
• CYP24A1 as a potential target for cancer therapy.

  2014cites this paper
• Baseline serum 25-hydroxyvitamin d levels in men undergoing radical prostatectomy: is there an association with adverse pathologic features?

  2014cites this paper
• The role of vitamin D in reducing cancer risk and progression

  2014cites this paper
• Novel Gemini vitamin D3 analogs: Large structure/function analysis and ability to induce antimicrobial peptide

  2014cites this paper
• Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.

  2014cites this paper
• Vitamin D Deficiency in Children With Cancer

  2014cites this paper
• Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

  2013cites this paper
• Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

  2013cites this paper
• Emerging roles of vitamin D in various spectra of diseases

  2013cites this paper
• Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor.

  2013cites this paper
• Is 1,25-dihydroxyvitamin D3 receptor expression a potential Achilles’ heel of CD44+ oral squamous cell carcinoma cells?

  2013cites this paper
• SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.

  2013cites this paper
• [Vitamin D and cancers].

  2013cites this paper
• Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells.

  2013cites this paper
• Vitamin D in the prevention and treatment of pancreatic cancer

  2013cites this paper
• Développement de nanoparticules polymères pour le ciblage des macrophages et la modulation des leurs fonctions physiologiques

  2013cites this paper
• Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients.

  2013cites this paper
• Vitamin D and Prostate Cancer

  2013cites this paper
• Vitamin D and cancer:present status and future prospects

  2013cites this paper
• Vitamin D and cancer

  2013cites this paper
• The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes

  2013cites this paper
• Erratum to: Is 1,25-Dihydroxyvitamin D3 Receptor Expression a Potential Achilles’ Heel of CD44+ Oral Squamous Cell Carcinoma Cells?

  2013cites this paper
• Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3

  2012cites this paper
• Vitamin D and Cancer

  2012cites this paper
• [Prostate cancer and chemotherapy: standards care and perspectives].

  2012cites this paper
• Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia

  2012cites this paper
• Retinoids Regulate the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells

  2012cites this paper
• Vitamin D and cancer: a review of molecular mechanisms.

  2012cites this paper
• Chimiothérapies cytotoxiques et cancer de la prostate : standards et perspectives

  2012cites this paper
• Relationship between PTH and PSA Values in Patients with Pathological Finding of Benign Prostatic Hyperplasia

  2012cites this paper
• Extraskeletal effects of vitamin D.

  2012cites this paper
• Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis.

  2012cites this paper
• Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study.

  2012cites this paper
• High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

  2012cites this paper
• The roles of cytochrome P450 enzymes in prostate cancer development and treatment.

  2012cites this paper
• Treatment Options in Hormone-Refractory Prostate Cancer

  2012cites this paper